SEC Form D filing

Tempest Therapeutics, Inc., 2026-04-03

An SEC Form D private-offering notice from Brisbane, CA, a $1,999,539 filer-stated offering target in Biotech. Filed 2026-04-03. The source filing is one click away. For companies that filed this week, open the live feed.

What this filing says

Tempest Therapeutics, Inc. site↗ Verified via SEC Form D

Nasdaq listed clinical stage biopharmaceutical company developing tumor targeted and immune mediated cancer therapies, including amezalpat for liver cancer.

Filed 2026-04-03Filed to raise $1,999,539First money in 2026-03-20Raised so far $1,999,539HQ (as filed) Brisbane, CASector Biotech web-verified against the company’s own siteStage (inferred) SeedCall status Call-ready
Source linked the Form D on EDGAR↗Website verified tempesttx.com↗Named in the filing 6 executives & directors

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.

Other Form D filings from the same week

each with its own page and its own EDGAR source